David Cooper

31.8k citations

57 papers · 2.4k indexed · 2 hit papers · h-index 25

Impact in

Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
Microbiology top 2%

Papers in

Infectious Diseases 24
- Antimicrobial Resistance in Staphylococcus 10
- SARS-CoV-2 and COVID-19 Research 8
Microbiology 8
- Bacterial Infections and Vaccines 7

Co-authors: Kathrin U. Jansen Kena A. Swanson Philip R. Dormitzer Mark Cutler Jing Zou Pei‐Yong Shi Xuping Xie Hongjie Xia
Journals: Vaccine (9 papers)Open Forum Infectious Diseases (9 papers)Human Vaccines & Immunotherapeutics (5 papers)The Journal of Infectious Diseases (5 papers)Journal of Virology (4 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

David Cooper

51 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants 2021 · 212 citations

Peers

Countries citing papers authored by David Cooper

Since Specialization

Citations

This map shows the geographic impact of David Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cooper more than expected).

Fields of papers citing papers by David Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cooper. The network helps show where David Cooper may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Cooper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Cooper Line = papers co-authored together David Cooper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa Open Forum Infectious Diseases ·Shabir A. Madhi, Eric A. F. Simões, Nicola P. Klein, Agnieszka Zareba, Philip R. Dormitzer, Daniel A. Scott, Alejandra Gurtman, William C. Gruber, Kathrin U. Jansen, David Cooper, Bing Cai, Beate Schmöele-Thoma, Kena A. Swanson	2025	0
2	P-596. Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results Open Forum Infectious Diseases ·Mark M. Davis, William Towner, Elliot DeHaan, Qin Jiang, Wen Li, Farah Rahman, Michael A. Patton, Laura Natalia Quintero Parra, Maria Maddalena Lino, Uzma Sarwar, J Arriagada, عاطف محمد أبو حميد, 小泉あずさ, Kevin Cannon, Elena Kalinina, David Cooper, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal	2025	1
3	Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age Vaccines ·Joel M. Neutel, AlexanderGerard, K. Rainer Massarsch, Kevin Cannon, Theresia Berliana Calya Putri, Ryan Newton, Emily Gomme, Wen Li, Federico Mensa, Özlem Türeci, Uğur Şahin, Kena A. Swanson, Iona Munjal, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin	2025	0
4	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine Nature Communications ·Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‐Yong Shi	2022	41
5	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants npj Vaccines ·Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Uğur Şahin, Xuping Xie, Philip R. Dormitzer, Pei‐Yong Shi	2022	6
6	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 Cell Host & Microbe ·Hongjie Xia, Jing Zou, Chaitanya Kurhade, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‐Yong Shi	2022	64
7	Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A Vaccine ·Hao Li, Michelle M. Kuttel, Neil Ravenscroft, Allison Thompson, A. Krishna Prasad, Aalto, Charles Y. Tan, David Cooper, Wendy Watson, Paul Liberator, Michael W. Pride, Kathrin U. Jansen, Annaliesa S. Anderson, Ingrid L. Scully	2022	24
8	Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine The Journal of Infectious Diseases ·James T. Peterson, Agnieszka Zareba, David Fitzpatrick, Brandon Essink, Daniel A. Scott, Kena A. Swanson, Augusto Daniel Ramírez Uhia, David Radley, David Cooper, Kathrin U. Jansen, Philip R. Dormitzer, William C. Gruber, Alejandra Gurtman	2021	31
9	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera Nature Medicine ·Xuping Xie, Yang Liu, Jianying Liu, Xianwen Zhang, Jing Zou, Camila R. Fontes-Garfias, Hongjie Xia, Kena A. Swanson, Mark Cutler, David Cooper, Vineet D. Menachery, Scott C. Weaver, Philip R. Dormitzer, Pei‐Yong Shi Hit paper breakdown →	2021	383
10	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants Nature ·Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Uğur Şahin, Xuping Xie, Philip R. Dormitzer, Pei‐Yong Shi Hit paper breakdown →	2021	212
11	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization npj Vaccines ·Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin R. Tompkins, Mark Cutler, David Cooper, Philip R. Dormitzer, Pei‐Yong Shi	2021	29
12	SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies Vaccine ·Elizabeth Begier, David Seiden, Michael A. Patton, Edward T. Zito, Joseph M. Severs, David Cooper, Joseph Eiden, William C. Gruber, Kathrin U. Jansen, Annaliesa S. Anderson, Alejandra Gurtman	2017	57
13	Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study Journal of Infection ·Helen Marshall, Michael D. Nissen, Peter Richmond, Sepehr Shakib, Qin Jiang, David Cooper, B. D. Roebuck, James Baber, Joseph Eiden, William C. Gruber, Kathrin U. Jansen, Annaliesa S. Anderson, Edward T. Zito, Douglas Girgenti	2016	9
14	Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention Expert Review of Vaccines ·Gustavo H. Dayan, Naglaa Mohamed, Ingrid L. Scully, David Cooper, Elizabeth Begier, Joseph Eiden, Kathrin U. Jansen, Alejandra Gurtman, Annaliesa S. Anderson	2016	115
15	A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults Vaccine ·Michael D. Nissen, Helen Marshall, Peter Richmond, Sepehr Shakib, Qin Jiang, David Cooper, B. D. Roebuck, James Baber, Joseph J. Eiden, William C. Gruber, Kathrin U. Jansen, Emilio A. Emini, Annaliesa S. Anderson, Edward T. Zito, Douglas Girgenti	2015	50
16	13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model Human Vaccines ·Philip Fernsten, Bartłomiej Mełges, Xinhong Yu, S. Saravanasundaram Sakthivel, 曹烨, Ashutosh Sancheti, Duzhang Zhu, David Cooper, Michael Hagen, Kathrin U. Jansen	2011	4
17	The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A Vaccine ·David Cooper, Xinhong Yu, Mohinder Sidhu, Moon H. Nahm, Philip Fernsten, Kathrin U. Jansen	2011	191
18	In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation Vaccine ·J. Erik Johnson, John W. Coleman, Narender K. Kalyan, Michael C. Caroll, Kevin J. Wright, Jennifer Obregon, Zhiyi Ma, Robert J. Natuk, David K. Clarke, Stephen A. Udem, David Cooper, R. Michael Hendry	2009	21
19	Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4 CTL responses Vaccine ·David Cooper, Michael W. Pride, Min Guo, Mark Cutler, Polina Barabanova, Farooq Nasar, Jingjing She, Victor Costa de Souza, Laura J. York, Eric M. Mishkin	2004	19
20	Biosynthesis of immunoglobulin in human immunoproliferative diseases. I. Kinetics of synthesis and secretion of immunoglobulin and protein by bone marrow cells in myeloma. PubMed ·Mengxin He, David Cooper, Muriel Balkanyi-Nehora, Ronald Penny	1978	13

About David Cooper

David Cooper is a scholar working on Infectious Diseases, Microbiology, Epidemiology, Animal Science and Zoology and Virology, having authored 57 papers that have together received 2.4k indexed citations. Recurring topics across this work include Respiratory viral infections research (21 papers), Pneumonia and Respiratory Infections (13 papers), Antimicrobial Resistance in Staphylococcus (10 papers), SARS-CoV-2 and COVID-19 Research (8 papers), Animal Virus Infections Studies (8 papers), Bacterial Infections and Vaccines (7 papers), Virus-based gene therapy research (6 papers) and Bacterial biofilms and quorum sensing (6 papers). The work is most often cited by research in Infectious Diseases (1.3k citations), Microbiology (209 citations), Epidemiology (827 citations), Animal Science and Zoology (212 citations) and Virology (81 citations). David Cooper has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Kathrin U. Jansen, Kena A. Swanson, Philip R. Dormitzer, Mark Cutler, Jing Zou, Pei‐Yong Shi, Xuping Xie, Hongjie Xia, Annaliesa S. Anderson and Kathrin U. Jansen. Their work appears in journals such as Vaccine, Open Forum Infectious Diseases, Human Vaccines & Immunotherapeutics, The Journal of Infectious Diseases and Journal of Virology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact